Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

225.99B

Market cap225.99B

Price-Earnings ratio

11.55

Price-Earnings ratio11.55

Dividend yield

2.50%

Dividend yield2.50%

Average volume

13.61M

Average volume13.61M

High today

$50.44

High today$50.44

Low today

$50.03

Low today$50.03

Open price

$50.29

Open price$50.29

Volume

913.73K

Volume913.73K

52 Week high

$71.80

52 Week high$71.80

52 Week low

$35.12

52 Week low$35.12

NVO News

TipRanks 1h

Vivani Advances GLP-1 Implant Program With Novo Nordisk

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 2h

Vivani Medical enters pact with Novo Nordisk to evaluate NPM-139

Vivani Medical (VANI) announced the signing of a new agreement with Novo Nordisk (NVO) to enable Novo Nordisk to evaluate NPM-139, the company’s semaglutide dru...

TipRanks 1d

Novo Nordisk Updates DKK 15 Billion Share Buyback as Treasury Stake Reaches 0.9%

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

54%

of 37 ratings

Buy

37.8%

Hold

54.1%

Sell

8.1%

More NVO News

Nasdaq 2d

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Key Points Viking Therapeutics could have a medicine on the market within two years. To capture market share, the new offering will need to fight a pair of ph...

The Motley Fool 4d

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Eli Lilly (LLY +1.35%) is a Wall Street darling thanks to its success in the GLP-1 weight-loss market. There's a problem here, however, because weight-loss drug...

Simply Wall St 4d

Novo Nordisk Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access

Novo Nordisk received major UK regulatory approval for its GLP-1 weight-loss pill version of Wegovy. The U.S. Medicare program began covering the company’s GLP...

Simply Wall St 6d

Novo Nordisk Stock Looks Below Fair Value On a 36% Slide

Novo Nordisk stock has had a tough run over the past three years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Fl...

CNBC 7d

Medicare will start covering obesity drugs for the first time. Here's what patients should know

Key Points Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary prog...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.